Tango Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Tango Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- TNGX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001819133
Board of directors
-
Aaron I. Davis · DirectorSince 2023
- Since 2023
-
Barbara Weber · Director · Director, Executive ChairSince 2023
-
John B. Ketchum · DirectorSince 2023
-
Joseph Lewis · DirectorSince 2023
-
Kanishka Pothula · DirectorSince 2023
-
Lesley Ann Calhoun · DirectorSince 2023
-
Mace Rothenberg · DirectorSince 2023
-
Malte Peters · Director · President & CEOSince 2023
-
Reid M. Huber · DirectorSince 2023
-
Robert Azelby · DirectorSince 2026
-
Sung Lee · DirectorSince 2026
Chief executives
Barbara Weber
· Chief Executive Officer
Dates unknown
Malte Peters
· President & CEO
Dates unknown
Board connections
5 of this board's directors also sit on 9 other boards.
- via Alexis Borisy and Barbara Weber
- via Alexis Borisy and Barbara Weber
- via Robert Azelby
- via Robert Azelby
- via Robert Azelby
- via Alexis Borisy
- via Reid M. Huber
- via Alexis Borisy
- via Mace Rothenberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $11,873,491
- 24 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Newcomb Jessica Officer (Principal Accounting Officer) | Open-market sale | −700 | $22.80 | $15,962 |
| Sep 22, 2026 | Newcomb Jessica Officer (Principal Accounting Officer) | Open-market sale | −5,100 | $23.97 | $122,238 |
| Sep 22, 2026 | Newcomb Jessica Officer (Principal Accounting Officer) | Open-market sale | −2,400 | $25.17 | $60,412 |
| Sep 1, 2026 | Crystal Adam Officer (President, R&D) | Option exercise | +27,000 | $5.20 | $140,400 |
| Sep 1, 2026 | Crystal Adam Officer (President, R&D) | Open-market sale | −27,000 | $22.37 | $603,909 |
| Aug 3, 2026 | Crystal Adam Officer (President, R&D) | Option exercise | +27,000 | $5.20 | $140,400 |
| Aug 3, 2026 | Crystal Adam Officer (President, R&D) | Open-market sale | −5,267 | $26.79 | $141,100 |
| Aug 3, 2026 | Crystal Adam Officer (President, R&D) | Open-market sale | −21,733 | $27.35 | $594,417 |
| Jul 1, 2026 | Crystal Adam Officer (President, R&D) | Option exercise | +27,000 | $5.20 | $140,400 |
| Jul 1, 2026 | Crystal Adam Officer (President, R&D) | Open-market sale | −19,629 | $29.34 | $575,962 |
| Jul 1, 2026 | Crystal Adam Officer (President, R&D) | Open-market sale | −7,371 | $30.25 | $222,946 |
| Jun 19, 2026 | Robert Azelby Director | Grant or award | +5,740 | — | — |
| Jun 5, 2026 | John B. Ketchum Director | Grant or award | +4,000 | — | — |
| Jun 5, 2026 | Lesley Ann Calhoun Director | Grant or award | +4,000 | — | — |
| Jun 5, 2026 | Mace Rothenberg Director | Grant or award | +4,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.